An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis

Trial Profile

An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone
  • Indications Amyloid light-chain amyloidosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2017 Primary endpoint (hematologic response) has been met,according to the results published in the blood.
    • 27 Jan 2017 Results published in the Blood
    • 27 Jan 2017 Status changed from active, no longer recruiting to completed,according to the results published in the blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top